COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Calcitriol in Preventing Lung Cancer in Smokers and Former Smokers at High Risk of Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00690924
Recruitment Status : Completed
First Posted : June 5, 2008
Results First Posted : October 11, 2017
Last Update Posted : June 4, 2018
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Roswell Park Cancer Institute

Brief Summary:

RATIONALE: Calcitriol may prevent lung cancer in patients with metaplasia or dysplasia of the lungs.

PURPOSE: This clinical trial is studying the side effects and best dose of calcitriol in preventing lung cancer in current smokers and former smokers at high risk of lung cancer.

Condition or disease Intervention/treatment Phase
Lung Cancer Precancerous Condition Tobacco Use Disorder Drug: calcitriol Other: laboratory biomarker analysis Other: pharmacological study Not Applicable

Detailed Description:



  • To establish the safety of calcitriol in patients at high risk of lung cancer.
  • To determine the dose-limiting toxicities of calcitriol in these patients.

OUTLINE: Patients receive oral calcitriol on day 1. Courses repeat every 2 weeks for 3 months in absence of unacceptable toxicity.

Patients undergo blood collection periodically for pharmacokinetic and molecular analysis.

After completion of study therapy, patients are followed periodically.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Pilot Study of Oral Calcitriol in Patients at High Risk for Lung Cancer
Actual Study Start Date : July 17, 2008
Actual Primary Completion Date : March 7, 2017
Actual Study Completion Date : March 7, 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Calcitriol

Arm Intervention/treatment
Experimental: Calcitriol Drug: calcitriol

Other: laboratory biomarker analysis
Correlative Study

Other: pharmacological study
Correlative Study

Primary Outcome Measures :
  1. Grade III-IV Toxicities or Any Grade II Toxicities Lasting More Than 2 Weeks [ Time Frame: 3 months ]

    Number of participants with Adverse Events, Grade II lasting more than two weeks or Grade III or higher, graded according to CTEP Version 4 of the NCI Common Terminology Criteria for Adverse Events (CTCAE) will be utilized for AE reporting.

    CTEP Version 4 of the CTCAE is identified and located at:

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 79 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Pathologically confirmed squamous metaplasia or squamous dysplasia of the lungs by autofluorescence bronchoscopy within the past 5 years
  • Must be a current or former smoker
  • No evidence of concurrent disease with lung cancer or head and neck cancer

    • History of treated lung cancer or head and neck cancer treated with curative intent allowed, provided that there has been no evidence of disease for > 1 year


  • ECOG performance status 0-1
  • Total granulocyte count > 1,500 x 10^9cells/L
  • Platelet count > 100,000 x 10^9cells/L
  • Calculated Creatinine clearance > 60 mL/min (using the Cockcroft-Gault formula)
  • Calcium concentration 50-300 mg/24 hours
  • Total bilirubin 0.2-1.3 mg%
  • ALT/AST ≤ 2.5 times upper limit of normal (ULN)
  • Alkaline phosphatase ≤ 2.5 times ULN
  • Albumin ≥ 2.5 g/dL
  • Ionized serum calcium normal (1.19-1.29 mmol/L)
  • Corrected serum calcium ≤ 10.2 mg/dL
  • Willing to attend all scheduled study visits, complete all study questionnaires, and allow biological specimen collection, including a bronchoscopy
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for at least 1 month after completion of study therapy
  • No life-threatening medical conditions that would preclude bronchoscopy, including but not limited to, any of the following:

    • Acute cardiac failure
    • Uncontrolled hypertension
    • Uncontrolled diabetes mellitus
    • Unstable coronary artery disease
  • No severe metabolic disorders that would preclude calcitriol administration
  • No history of any other malignancy within 3 years except for nonmelanoma skin cancer or cervical carcinoma in situ
  • No history or evidence of kidney stones
  • No patients who are susceptible to calcium-related dysrhythmias
  • No known hypersensitivity to calcitriol
  • No known allergies to tree nuts (i.e., almonds)


  • At least 2 months since prior and no concurrent calcium supplements
  • Concurrent multivitamin supplement allowed provided the amount of vitamin D in the supplement is not in excess of the recommended daily dose
  • No concurrent thiazides, phenobarbital, or digitalis
  • No concurrent digoxin
  • No concurrent bile acid binding drugs (i.e., cholestyramine, colestipol)
  • No concurrent danazol or aluminum-based antacids
  • No concurrent ketoconazole or other azole antifungals

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00690924

Layout table for location information
United States, New York
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263-0001
Sponsors and Collaborators
Roswell Park Cancer Institute
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: Mary Reid, PhD Roswell Park Cancer Institute
  Study Documents (Full-Text)

Documents provided by Roswell Park Cancer Institute:
Layout table for additonal information
Responsible Party: Roswell Park Cancer Institute Identifier: NCT00690924    
Obsolete Identifiers: NCT01896804
Other Study ID Numbers: CDR0000596506
P30CA016056 ( U.S. NIH Grant/Contract )
I 90206
First Posted: June 5, 2008    Key Record Dates
Results First Posted: October 11, 2017
Last Update Posted: June 4, 2018
Last Verified: May 2018
Keywords provided by Roswell Park Cancer Institute:
lung cancer
tobacco use disorder
squamous lung dysplasia
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Precancerous Conditions
Tobacco Use Disorder
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Calcium Channel Agonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasoconstrictor Agents
Growth Substances
Bone Density Conservation Agents